NewKerala.com

Gene Editing Breakthrough: How Australia's One-Time Therapy Halves Bad Cholesterol

Australian researchers have pioneered a groundbreaking gene editing therapy that could revolutionize cholesterol management. The one-time CRISPR-based treatment successfully reduced bad cholesterol and triglycerides by up to 60% in clinical trials. This innovative approach offers hope for patients with challenging lipid disorders by providing a potentially single-course treatment with lasting effects. The research, published in the New England Journal of Medicine, represents a significant advancement in preventative heart disease strategies.

Key Points: Australia Gene Editing Trial Cuts Cholesterol CRISPR Therapy

  • First human trial uses CRISPR-Cas9 to switch off ANGPTL3 gene
  • Single treatment reduces LDL cholesterol by 50% in participants
  • Therapy shows potential for long-lasting cholesterol management
  • Targets patients with difficult-to-treat lipid disorders
2 min read

Australia leads first human trial of one-time gene editing therapy to halve bad cholesterol

Australian researchers successfully use gene editing to dramatically reduce cholesterol levels in groundbreaking medical trial targeting heart disease prevention

"The possibility of a single-course treatment with lasting effects could be a major step in how we prevent heart disease - Stephen Nicholls, Victorian Heart Hospital Director"

Melbourne, Nov 10

Researchers in Australia have led a first-in-human trial for a breakthrough gene-editing therapy that halves bad cholesterol and triglycerides in people with difficult-to-treat lipid disorders.

The trial tested CTX310, a one-time CRISPR-Cas9 gene-editing therapy that uses fat-based particles to carry CRISPR editing tools into the liver, switching off the ANGPTL3 gene. Turning off this gene lowers LDL (bad) cholesterol and triglycerides, two blood fats linked to heart disease, according to a statement released Monday by Australia's Monash University.

The Victorian Heart Hospital, operated by Monash Health in partnership with Monash University, treated three of 15 patients aged 18-75 years with difficult-to-treat lipid disorders in phase 1 of the global trial conducted across Australia, New Zealand, and Britain, the statement said, Xinhua news agency reported.

At the highest dose, a single-course treatment with CTX310 resulted in a mean reduction of LDL cholesterol by 50 per cent and triglycerides by 55 per cent, remaining low for at least 60 days after two weeks of treatment, it said, adding LDL cholesterol and triglycerides were reduced by nearly 60 per cent among all participants with various doses, with only mild, short-term side effects reported.

Importantly, CTX310 is the first therapy to achieve large reductions in both LDL cholesterol and triglycerides at the same time, marking a potential breakthrough for people with mixed lipid disorders who have elevations in both, according to the trial published in the New England Journal of Medicine.

"The possibility of a single-course treatment with lasting effects could be a major step in how we prevent heart disease," said Stephen Nicholls, Director of the Victorian Heart Hospital, and study lead investigator.

"It makes treatment easier, reduces ongoing costs, relieves pressure on the health system, all while improving a person's quality of life," Nicholls said, emphasising plans to focus on larger and more diverse patient populations in future trials of CTX310.

- IANS

Share this article:

Reader Comments

R
Rohit P
Great breakthrough, but I worry about the long-term effects of gene editing. We need to be cautious - what if there are unintended consequences years later? Still, promising for those with severe cholesterol issues.
A
Ananya R
My father has been struggling with high cholesterol for years despite medications. This gives us hope! The fact that it's one-time treatment could save so much money on lifelong medicines. When will this reach India? 🤔
V
Vikram M
Impressive results - 50% reduction in bad cholesterol is huge! But the real question is cost. Will ordinary people in countries like India be able to afford such advanced treatments, or will it remain for the wealthy only?
S
Sarah B
As someone who works in healthcare, this could revolutionize cardiac care. The reduction in ongoing costs and hospital visits would be massive for our overburdened health systems. Hope Indian researchers can collaborate on such projects too.
K
Karthik V
Wonderful to see medical science advancing! But let's not forget prevention - we Indians need to focus more on healthy diets and exercise rather than waiting for high-tech solutions. Both approaches are important. 💪

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50